Positive CHMP opinion recommends extending use of Adtralza® (tralokinumab) to adolescents (12-17 years old) in the European Union (EU) Recommendation supported by data from the Phase 3 ECZTRA 6 trial
A review decision by the European Medicines Agency (EMA) is expected in the second half of 2023 If approved, sparsentan will be a first-in-class treatment to address the significant unmet medical nee
− If Approved, Maribavir Would be the First and Only Inhibitor of CMV-specific UL97 Protein Kinase in the EU for Treatment of Adults with Post-transplant CMV Refractory (With or Without Resistance) to
− Company to Feature 15 Company-Sponsored and Nine Collaborative Abstracts in Oncology and Hematology − Oral Presentations Include Updated Results from Phase 3 OPTIC Trial of ICLUSIG® (ponatinib) and
/newsonfloor/media/post_banners/rHgTnGXsBf9pULkVgijv.jpg)
/newsonfloor/media/post_banners/3cOuYRvLhOUGowZbls9m.jpg)
/newsonfloor/media/post_banners/YHKHbR4De3REmxNp3yH3.jpeg)
/newsonfloor/media/post_banners/8etqEmbMo1yxibyZl33D.jpg)
/newsonfloor/media/post_banners/v5lIoAtwmYrAR5I4OPXg.jpg)
